Oral sessions summaries
Results of the eValuation of ERTugliflozinEffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
Expert Commentary by Mark Cooper, MB, BS, PhD
ADA 2020 - Oral session
DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?!
Expert Commentary by Prof. Francesco Giorgino, MD
ADA 2020 - Oral session
Analyses of First Plus Recurrent Cardiovascular and Hospitalization Events in the CAROLINA Trial
Expert Commentary by Luca Monge, MD
ADA 2020 - Oral session
Association of Frequency of Hypoglycemic Episodes with Incident Cardiovascular Events in Adults with Type 2 Diabetes Mellitus: A National Database Study
Expert commentary by Luca Monge, MD
ADA 2020 - Oral session
Efficacy and Safety of Dulaglutide 3 mg and 4.5 mg vs. Dulaglutide 1.5 mg: 52-Week Results from AWARD-11
Expert Commentary by Paolo Fiorina, MD, PhD and Ida Pastore, MD
ADA 2020 - Oral session
Acute Declines in eGFR During Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE
Expert Commentary by Luca Monge, MD
ADA 2020 - Oral session
Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease
Expert Commentary by Martin Haluzík, MD
ADA 2020 - Oral session
Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER
Expert commentary by Vivian A. Fonseca, MD, FRCP
ADA 2020 - Oral session
Advanced Hybrid Closed-Loop Pivotal Safety Study
Expert commentary by Amy Sanghavi Shah, MD, MS
ADA 2020 - Oral session
FLAIR—An NIDDK-Sponsored International, Multisite Randomized Crossover Trial of AHCL vs. 670G
Expert commentary by Amy Sanghavi Shah, MD, MS
ADA 2020 - Oral session
New Zealand AHCL Randomized Crossover Trial
Expert commentary by David Maahs, MD, PhD
ADA 2020 - Oral session
Horizon Automated Glucose Control System Pre-pivotal Trial Data
Expert commentary by Amy Sanghavi Shah, MD, MS
ADA 2020 - Oral session
New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS)
Expert commentary by Dana M. Dabelea, MD, PhD
ADA 2020 - Oral session
Update from the TEDDY Study
Expert Commentary by Prof. Tatjana Milenkovic, MD
ADA 2020 - Oral session
Twenty Years of Pediatric Diabetes Surveillance- What Do We Know and Why It Matters - The SEARCH for Diabetes in Youth Study
Expert commentary by Dana M. Dabelea, MD, PhD
ADA 2020 - Oral session
Population Health Efforts in the Prevention and Treatment of Diabetes
Expert Commentary by Prof. Florian Toti, MD
ADA 2020 - Oral session
All-Cause Mortality over 16 Years in Look AHEAD
Expert Commentary by Martin Haluzík, MD
ADA 2020 - Oral session
Comparison of Pancreas vs. Islet Transplantation Outcomes from a Large Single Center
ADA 2020 - Oral session
New Insights from the Restoring Insulin Secretion (RISE) Study—Differences between Adults and Youth with Prediabetes and Type 2 Diabetes
Expert commentary by Dana M. Dabelea, MD, PhD
ADA 2020 - Oral session
Glycaemia, Beta-Cell Function, and Incretin Hormones Post-OGTT One Year after Gastric Bypass and Sleeve Gastrectomy in Patients with Morbid Obesity and Type 2 Diabetes: An RCT (Oseberg Study)
Expert Commentary by Prof. Tatjana Milenkovic, MD
ADA 2020 - Oral session
Differences in Time-in-Range, Glycemic Variability, and the Glucose Management Indicator in Pregnant Women with Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes
Expert commentary by Denice Feig, MD, MSc, FRCPC
ADA 2020 - Oral session